Search

Your search keyword '"Lima, CA"' showing total 12 results
Start Over Author "Lima, CA" Database OAIster
12 results on '"Lima, CA"'

1. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author

Allemani, C, Matsuda, T, Di Carlo, V, Harewood, R, Matz, M, Nikšić, M, Bonaventure, A, Valkov, M, Johnson, CJ, Estève, J, Ogunbiyi, OJ, Azevedo e Silva, G, Chen, WQ, Eser, S, Engholm, G, Stiller, CA, Monnereau, A, Woods, RR, Visser, O, Lim, GH, Aitken, J, Weir, HK, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Meguenni, K, Regagba, D, Bayo, S, Cheick Bougadari, T, Manraj, SS, Bendahhou, K, Fabowale, A, Bradshaw, D, Somdyala, NIM, Kumcher, I, Moreno, F, Calabrano, GH, Espinola, SB, Carballo Quintero, B, Fita, R, Diumenjo, MC, Laspada, WD, Ibañez, SG, Lima, CA, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Rebelo, MS, Santos, MO, Galaz, JC, Aparicio Aravena, M, Sanhueza Monsalve, J, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Garcia, LS, Arias-Ortiz, NE, Morantes, D, Jurado, DM, Yépez Chamorro, MC, Delgado, S, Ramirez, M, Galán Alvarez, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Castillo, J, Mendoza, M, Cueva, P, Yépez, JG, Bhakkan, B, Deloumeaux, J, Joachim, C, Macni, J, Carrillo, R, Shalkow Klincovstein, J, Rivera Gomez, R, Poquioma, E, Tortolero-Luna, G, Zavala, D, Alonso, R, Barrios, E, Eckstrand, A, Nikiforuk, C, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Allemani, C, Matsuda, T, Di Carlo, V, Harewood, R, Matz, M, Nikšić, M, Bonaventure, A, Valkov, M, Johnson, CJ, Estève, J, Ogunbiyi, OJ, Azevedo e Silva, G, Chen, WQ, Eser, S, Engholm, G, Stiller, CA, Monnereau, A, Woods, RR, Visser, O, Lim, GH, Aitken, J, Weir, HK, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Meguenni, K, Regagba, D, Bayo, S, Cheick Bougadari, T, Manraj, SS, Bendahhou, K, Fabowale, A, Bradshaw, D, Somdyala, NIM, Kumcher, I, Moreno, F, Calabrano, GH, Espinola, SB, Carballo Quintero, B, Fita, R, Diumenjo, MC, Laspada, WD, Ibañez, SG, Lima, CA, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Rebelo, MS, Santos, MO, Galaz, JC, Aparicio Aravena, M, Sanhueza Monsalve, J, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Garcia, LS, Arias-Ortiz, NE, Morantes, D, Jurado, DM, Yépez Chamorro, MC, Delgado, S, Ramirez, M, Galán Alvarez, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Castillo, J, Mendoza, M, Cueva, P, Yépez, JG, Bhakkan, B, Deloumeaux, J, Joachim, C, Macni, J, Carrillo, R, Shalkow Klincovstein, J, Rivera Gomez, R, Poquioma, E, Tortolero-Luna, G, Zavala, D, Alonso, R, Barrios, E, Eckstrand, A, Nikiforuk, C, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, and Ryan, S

Abstract

© 2018 Elsevier Ltd Background: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods: CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000–14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010–14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By

Published
2018

2. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author

Allemani, C, Matsuda, T, Di Carlo, V, Harewood, R, Matz, M, Nikšić, M, Bonaventure, A, Valkov, M, Johnson, CJ, Estève, J, Ogunbiyi, OJ, Azevedo e Silva, G, Chen, WQ, Eser, S, Engholm, G, Stiller, CA, Monnereau, A, Woods, RR, Visser, O, Lim, GH, Aitken, J, Weir, HK, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Meguenni, K, Regagba, D, Bayo, S, Cheick Bougadari, T, Manraj, SS, Bendahhou, K, Fabowale, A, Bradshaw, D, Somdyala, NIM, Kumcher, I, Moreno, F, Calabrano, GH, Espinola, SB, Carballo Quintero, B, Fita, R, Diumenjo, MC, Laspada, WD, Ibañez, SG, Lima, CA, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Rebelo, MS, Santos, MO, Galaz, JC, Aparicio Aravena, M, Sanhueza Monsalve, J, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Garcia, LS, Arias-Ortiz, NE, Morantes, D, Jurado, DM, Yépez Chamorro, MC, Delgado, S, Ramirez, M, Galán Alvarez, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Castillo, J, Mendoza, M, Cueva, P, Yépez, JG, Bhakkan, B, Deloumeaux, J, Joachim, C, Macni, J, Carrillo, R, Shalkow Klincovstein, J, Rivera Gomez, R, Poquioma, E, Tortolero-Luna, G, Zavala, D, Alonso, R, Barrios, E, Eckstrand, A, Nikiforuk, C, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Allemani, C, Matsuda, T, Di Carlo, V, Harewood, R, Matz, M, Nikšić, M, Bonaventure, A, Valkov, M, Johnson, CJ, Estève, J, Ogunbiyi, OJ, Azevedo e Silva, G, Chen, WQ, Eser, S, Engholm, G, Stiller, CA, Monnereau, A, Woods, RR, Visser, O, Lim, GH, Aitken, J, Weir, HK, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Meguenni, K, Regagba, D, Bayo, S, Cheick Bougadari, T, Manraj, SS, Bendahhou, K, Fabowale, A, Bradshaw, D, Somdyala, NIM, Kumcher, I, Moreno, F, Calabrano, GH, Espinola, SB, Carballo Quintero, B, Fita, R, Diumenjo, MC, Laspada, WD, Ibañez, SG, Lima, CA, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Rebelo, MS, Santos, MO, Galaz, JC, Aparicio Aravena, M, Sanhueza Monsalve, J, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Garcia, LS, Arias-Ortiz, NE, Morantes, D, Jurado, DM, Yépez Chamorro, MC, Delgado, S, Ramirez, M, Galán Alvarez, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Castillo, J, Mendoza, M, Cueva, P, Yépez, JG, Bhakkan, B, Deloumeaux, J, Joachim, C, Macni, J, Carrillo, R, Shalkow Klincovstein, J, Rivera Gomez, R, Poquioma, E, Tortolero-Luna, G, Zavala, D, Alonso, R, Barrios, E, Eckstrand, A, Nikiforuk, C, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, and Ryan, S

Abstract

© 2018 Elsevier Ltd Background: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods: CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000–14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010–14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By

Published
2018

3. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)

Author

Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, C.Stefan, D, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, C.Stefan, D, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, and Robb, KI

Abstract

© 2016 Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995–2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. Results During 2005–2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. Conclusions The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.

Published
2017

4. Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413](S0090825816314974)(10.1016/j.ygyno.2016.10.019)

Author

Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, and Robb, KI

Abstract

© 2017 Unfortunately, the original publication of the article includes errors in the author list for the CONCORD Working Group members (pages 411–412). The CONCORD Working Group members for the Registro de Câncer de São Paulo (Brazil) should read MRDO Latorre, LF Tanaka; the correct affiliation for DC Stefan is Umtata University (South Africa); the correct affiliation for N Bhoo-Pathy is University of Malaya (Malaysia); the correct affiliation for O Chimedsuren is Mongolian National University of Medical Sciences – MNUMS (Mongolia); the affiliation for G Gatta and M Sant should read Fondazione IRCCS Istituto Nazionale dei Tumori (Italy); and for the United Kingdom, correct initials for C Stiller should read CA Stiller. Due to a miscommunication during the process of transferring this manuscript from our editorial team to Production, the CONCORD Working Group authors were not properly indexed in PubMed. This has now been corrected online. The publisher would like to apologise for any inconvenience caused.

Published
2017

5. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

Author

Matz, M, Coleman, MP, Carreira, H, Salmerón, D, Chirlaque, MD, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, Stuart-Panko, H, Matz, M, Coleman, MP, Carreira, H, Salmerón, D, Chirlaque, MD, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, and Stuart-Panko, H

Abstract

© 2016 Elsevier Inc. Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99 years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005–09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20–45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

Published
2017

6. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)

Author

Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, C.Stefan, D, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, C.Stefan, D, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, and Robb, KI

Abstract

© 2016 Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995–2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. Results During 2005–2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. Conclusions The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.

Published
2017

7. Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413](S0090825816314974)(10.1016/j.ygyno.2016.10.019)

Author

Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, Matz, M, Coleman, MP, Sant, M, Chirlaque, MD, Visser, O, Gore, M, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, and Robb, KI

Abstract

© 2017 Unfortunately, the original publication of the article includes errors in the author list for the CONCORD Working Group members (pages 411–412). The CONCORD Working Group members for the Registro de Câncer de São Paulo (Brazil) should read MRDO Latorre, LF Tanaka; the correct affiliation for DC Stefan is Umtata University (South Africa); the correct affiliation for N Bhoo-Pathy is University of Malaya (Malaysia); the correct affiliation for O Chimedsuren is Mongolian National University of Medical Sciences – MNUMS (Mongolia); the affiliation for G Gatta and M Sant should read Fondazione IRCCS Istituto Nazionale dei Tumori (Italy); and for the United Kingdom, correct initials for C Stiller should read CA Stiller. Due to a miscommunication during the process of transferring this manuscript from our editorial team to Production, the CONCORD Working Group authors were not properly indexed in PubMed. This has now been corrected online. The publisher would like to apologise for any inconvenience caused.

Published
2017

8. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

Author

Matz, M, Coleman, MP, Carreira, H, Salmerón, D, Chirlaque, MD, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, Stuart-Panko, H, Matz, M, Coleman, MP, Carreira, H, Salmerón, D, Chirlaque, MD, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, OJ, Bradshaw, D, Somdyala, NIM, Stefan, DC, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo de Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, DE, McClure, C, Vriends, KA, Bertrand, C, Louchini, R, Robb, KI, and Stuart-Panko, H

Abstract

© 2016 Elsevier Inc. Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99 years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005–09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20–45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

Published
2017

9. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

Author

Bonaventure, A, Harewood, R, Stiller, CA, Gatta, G, Clavel, J, Stefan, DC, Carreira, H, Spika, D, Marcos-Gragera, R, Peris-Bonet, R, Piñeros, M, Sant, M, Kuehni, CE, Murphy, MFG, Coleman, MP, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, de Oliveira, EL, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Bonaventure, A, Harewood, R, Stiller, CA, Gatta, G, Clavel, J, Stefan, DC, Carreira, H, Spika, D, Marcos-Gragera, R, Peris-Bonet, R, Piñeros, M, Sant, M, Kuehni, CE, Murphy, MFG, Coleman, MP, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, de Oliveira, EL, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, and Ruta, M

Abstract

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. Methods Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0–14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995–99, 2000–04, and 2005–09), sex, and age at diagnosis (<1, 1–4, 5–9, and 10–14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Findings We analysed data from 89 828 children from 198 registries in 53 countries. During 1995–99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1–18·2) in the Chinese registries to 86·8% (81·6–92·0) in Austria. International differences in 5-year survival for childhood leuka

Published
2017

10. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

Author

Bonaventure, A, Harewood, R, Stiller, CA, Gatta, G, Clavel, J, Stefan, DC, Carreira, H, Spika, D, Marcos-Gragera, R, Peris-Bonet, R, Piñeros, M, Sant, M, Kuehni, CE, Murphy, MFG, Coleman, MP, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, de Oliveira, EL, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, Ruta, M, Bonaventure, A, Harewood, R, Stiller, CA, Gatta, G, Clavel, J, Stefan, DC, Carreira, H, Spika, D, Marcos-Gragera, R, Peris-Bonet, R, Piñeros, M, Sant, M, Kuehni, CE, Murphy, MFG, Coleman, MP, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, de Oliveira, EL, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, and Ruta, M

Abstract

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. Methods Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0–14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995–99, 2000–04, and 2005–09), sex, and age at diagnosis (<1, 1–4, 5–9, and 10–14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Findings We analysed data from 89 828 children from 198 registries in 53 countries. During 1995–99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1–18·2) in the Chinese registries to 86·8% (81·6–92·0) in Austria. International differences in 5-year survival for childhood leuka

Published
2017

11. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

Author

Allemani, C, Weir, HK, Carreira, H, Harewood, R, Spika, D, Wang, XS, Bannon, F, Ahn, JV, Johnson, CJ, Bonaventure, A, Marcos-Gragera, R, Stiller, C, Azevedo E Silva, G, Chen, WQ, Ogunbiyi, OJ, Rachet, B, Soeberg, MJ, You, H, Matsuda, T, Bielska-Lasota, M, Storm, H, Tucker, TC, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, Stefan, CD, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, E, Pugh, FV, Torrent, ME, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Koifman, S, Galaz, JC, Moya, JA, Herrmann, DA, Jofre, AM, Uribe, CJ, Bravo, LE, Lopez Guarnizo, G, Jurado, DM, Yepes, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Allemani, C, Weir, HK, Carreira, H, Harewood, R, Spika, D, Wang, XS, Bannon, F, Ahn, JV, Johnson, CJ, Bonaventure, A, Marcos-Gragera, R, Stiller, C, Azevedo E Silva, G, Chen, WQ, Ogunbiyi, OJ, Rachet, B, Soeberg, MJ, You, H, Matsuda, T, Bielska-Lasota, M, Storm, H, Tucker, TC, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, Stefan, CD, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, E, Pugh, FV, Torrent, ME, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Koifman, S, Galaz, JC, Moya, JA, Herrmann, DA, Jofre, AM, Uribe, CJ, Bravo, LE, Lopez Guarnizo, G, Jurado, DM, Yepes, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, and Ryan, S

Abstract

© 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75 000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in B

Published
2015

12. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

Author

Allemani, C, Weir, HK, Carreira, H, Harewood, R, Spika, D, Wang, XS, Bannon, F, Ahn, JV, Johnson, CJ, Bonaventure, A, Marcos-Gragera, R, Stiller, C, Azevedo E Silva, G, Chen, WQ, Ogunbiyi, OJ, Rachet, B, Soeberg, MJ, You, H, Matsuda, T, Bielska-Lasota, M, Storm, H, Tucker, TC, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, Stefan, CD, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, E, Pugh, FV, Torrent, ME, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Koifman, S, Galaz, JC, Moya, JA, Herrmann, DA, Jofre, AM, Uribe, CJ, Bravo, LE, Lopez Guarnizo, G, Jurado, DM, Yepes, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Allemani, C, Weir, HK, Carreira, H, Harewood, R, Spika, D, Wang, XS, Bannon, F, Ahn, JV, Johnson, CJ, Bonaventure, A, Marcos-Gragera, R, Stiller, C, Azevedo E Silva, G, Chen, WQ, Ogunbiyi, OJ, Rachet, B, Soeberg, MJ, You, H, Matsuda, T, Bielska-Lasota, M, Storm, H, Tucker, TC, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, Stefan, CD, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, E, Pugh, FV, Torrent, ME, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Koifman, S, Galaz, JC, Moya, JA, Herrmann, DA, Jofre, AM, Uribe, CJ, Bravo, LE, Lopez Guarnizo, G, Jurado, DM, Yepes, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, and Ryan, S

Abstract

© 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75 000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in B

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results